Company
eve Sleep PLC
LON:EVE
We believe in the perfect start. Every great day starts the night before. Good sleep and great starts are too important to be elitist. For too long, mattresses have been sold through expensive stores at massively inflated prices. So we set out to create eve. A mattress that is simply beautiful and beautifully simple, and available to everyone at a surprisingly fair price.
113 stories · page 2 of 6
Evgen Pharma hails important step in development of SFX-01
The aim of the phase I/Ib study is to understand how SFX-01 works in its new formulation
Eve Sleep bought by Bensons for Bed after going into administration
The AIM-listed company's shares were suspended from trading on AIM yesterday morning
Eve Sleep calls in administrators after unsuccessful sale and funding talks
The sleep wellness brand company had warned last month that it needed further funding after reporting a doubling in pre-tax losses for the first half
Evgen Pharma says new tack with brain cancer programme extends cash runway
The company announced this morning that it will embark on an investigator-sponsored clinical study of SFX-01 in glioblastoma
Evgen Pharma sees forecasts upgraded following major partnership deal with Stalicla
The partnership is for the investigation of Evgen's lead SFX-01 as a potential treatment for autism spectrum disorder and other central nervous system disorders
Archive
Small Cap Feast - Evgen Pharma, I3 Energy, Mosman Oil and Gas, and more...
10 October 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Cooks Coffee Company ltd, an i
Evgen licenses neuro disorder rights of SFX-01 to autism specialist
Evgen and Swiss group Stalicla will collaborate initially on a clinical programme in autism spectrum disorder
Evgen Pharma gets green light to assess new coated tablet form of lead asset
"These approvals will enable us to launch our healthy volunteer study on schedule in the fourth quarter,” said Evgen chief executive, Dr Huw Jones
Archive
Eve Sleep will need a further cash injection as sale talks stall
“We are doing everything possible to manage the business through these incredibly difficult times, whilst speaking with potential investors and strategic partners," Cheryl Calverley, chief executive officer, said
Evgen Pharma and Michigan University to collaborate in colorectal cancer study
This new project is Evgen's fifteenth pre-clinical collaboration
Archive
Small Cap Feast - Evgen Pharma, Franchise Brands, and more...
24 May 2022*A corporate client of Hybridan LLPDish of the dayJoiners:No Joiners Today.Leavers:Clipper Logistics has left the Main Market following a Cash takeover.What’s cooking in the IPO kitchen?According to news reports, The Very Group,
Evgen Pharma launches new collaboration for lead asset
"This will be our 14th academic collaboration and is part of our ongoing strategy," said Evgen CEO Dr Huw Jones
Evgen Pharma expanding its work with the Manchester Breast Centre
The centre is part of the University of Manchester's School of Medical Sciences
Archive
Invinity Energy surges after winning government grant for storage project
A look at the major movers on the London market on Wednesday
Archive
Small Cap Wrap - Ten Lifestyle Group, Plus500, Evgen Pharma and more...
Ten Lifestyle Group 116.5p £97.3m (LON:TENG) The technology-enabled, global concierge platform for the world's wealthy and mass affluent, has won a contract with one of Japan's largest wealth management businesses.
Evgen Pharma signs option to review sulforaphane analogues developed by Spanish researchers
The analogues have the potential for differentiation from the company's lead product, SFX-01, in terms of product formulation
Evgen Pharma at a significant value inflexion point, says City broker
The update from finnCap followed progress with the regulators on both sides of the Atlantic
Evgen Pharma makes headway with regulators on both sides of the Atlantic
Chief executive Huw Jones said he was 'delighted' with the progress that has been made with the Medicines and Healthcare products Regulatory Agency here in the UK and the Food and Drug Administration in the US
Evgen Pharma gears up for a busy start to 2022
"The last six months have yielded further positive preclinical data to support the potential of SFX-01 in a number of cancers and an orphan drug designation in the USA for malignant glioma,” said chief executive Dr Huw Jones